SCHEMBL8045577

SCHEMBL8045577

COc1ccc(Cl)cc1S(=O)(=O)N[C@@H]1C[C@H](CNC(=O)Oc2ccccc2)N(C(=O)OC(C)(C)C)C1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CPT2 P23786 1/20 0.50
CPT1A P50416 1/20 0.50
CPT1B Q92523 1/20 0.50
DRD2 P14416 4/20 0.41
ADRA1D P25100 4/20 0.41
ADRA1A P35348 4/20 0.41
ADRA1B P35368 4/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
NR1H2 P55055 1/20 0.39
CTSL P07711 1/20 0.39
CTSS P25774 1/20 0.39
CTSK P43235 1/20 0.39
CTSC P53634 1/20 0.39
ATM Q13315 1/20 0.39
STS P08842 1/20 0.38
AHCY P23526 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8064342 0.92 CTSL (0.47) CPT2CPT1ACPT1BDRD2ADRA1D
SCHEMBL4294665 0.91 CPT2 (0.53) CPT2CPT1ACPT1BDRD2ADRA1D
SCHEMBL13662066 0.87 CPT1A (0.54) CPT2CPT1ACPT1BDRD2ADRA1D
SCHEMBL8067031 0.84 CPT2 (0.47) CPT2CPT1ACPT1BDRD2ADRA1D
SCHEMBL4301195 0.83 CTSL (0.51) CPT2CPT1ACPT1BDRD2ADRA1D
SCHEMBL8063332 0.82 CTSL (0.44) KMT2ANR1H2CTSLCTSSCTSK
SCHEMBL8047069 0.81 CPT2 (0.46) CPT2CPT1ACPT1BDRD2ADRA1D
SCHEMBL3948684 0.81 CPT2 (0.44) CPT2CPT1ACPT1BDRD2ADRA1D
SCHEMBL3946155 0.80 CTSL (0.52) CPT2CPT1ACPT1BDRD2ADRA1D
SCHEMBL13663720 0.80 CTSL (0.52) CPT2CPT1ACPT1BDRD2ADRA1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264431-A1 NOVEL CATHEPSIN C INHIBITORS AND THEIR USE GLAXO GROUP LIMITED (GB) 2009-10-22 US disclosed
WO-2009026197-A1 NOVEL CATHEPSIN C INHIBITORS AND THEIR USE GLAXO GROUP LIMITED (GB) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264431-A1 NOVEL CATHEPSIN C INHIBITORS AND THEIR USE CTSB, CTSS, CTSF CPT2 3009/4885CPT1A 3354/4885CPT1B 1975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.